AbbVie Successfully Transitions Revenue from Humira to New Immunology and Neuroscience Growth Engines
AbbVie Inc. (ABBV) is successfully navigating the loss of exclusivity for its former blockbuster drug, Humira, by leveraging a new generation of immunology treatments. The company's newer drugs, Skyrizi and Rinvoq, have become significant revenue drivers, collectively generating over $8 billion in quarterly revenue to offset previous losses. Beyond immunology, AbbVie is seeing rapid expansion in its neuroscience division and maintains a stable presence in the aesthetics market through Allergan Aesthetics. With second-quarter revenue up 10.2% to $17 billion and adjusted earnings per share rising nearly 23%, the company demonstrates strong profitability and a robust capacity to support its growing dividend.
Tickers: $ABBV
Topics: Biopharmaceuticals Drug Sales Earnings Per Share Revenue Growth